Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer
- 20 March 2014
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 135 (8), 1961-1969
- https://doi.org/10.1002/ijc.28829
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Contrasting effects of sunitinib within in vivo models of metastasisAngiogenesis, 2012
- Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving SorafenibClinical Cancer Research, 2011
- Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette TransportersCancer Research, 2010
- Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignanciesBMC Cancer, 2010
- An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancerAnnals of Oncology, 2010
- Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancerBreast Cancer Research and Treatment, 2010
- Biomarkers of angiogenesis and their role in the development of VEGF inhibitorsBritish Journal of Cancer, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences of the United States of America, 2003
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001